GenFleet’s GFS202A Becomes World’s First Cachexia Bispecific Antibody to Show Clinical Activity at ASCO 2026
GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) presented preliminary Phase I clinical data for GFS202A, the...
LaNova’s CLDN18.2 ADC LM-302 Shows 15-Month PFS in Gastric Cancer Phase II Data at ASCO 2026
LaNova Medicines Ltd., a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), presented Phase II clinical...
Alphamab-CSPC’s HER2 Bispecific Antibody Anbenitamab Wins NMPA Approval for Refractory Gastric Cancer with 75% PFS Benefit
China’s National Medical Products Administration (NMPA) has granted approval for anbenitamab, a HER2 bispecific antibody...
Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design
Lynk Pharmaceuticals Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted clearance...
CF PharmTech’s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease
CF PharmTech Inc. (HKG: 2652) announced that China’s National Medical Products Administration (NMPA) has granted...
Peijia Medical Secures Exclusive China Distribution Rights for B. Braun’s SeQuent Please CIS Intracranial Drug-Coated Balloon
Peijia Medical Ltd. (HKG: 9996) announced an exclusive distribution agreement with B. Braun Melsungen AG...
Basecare Medical Secures NMPA Category III Approval for Gems Oocyte Retrieval Solution in China’s IVF Market
Basecare Medical Device Co., Ltd. (HKG: 2170), a specialist in high-throughput sequencing-based assisted reproduction technologies,...
Shandong Boan Submits Dual Denosumab Biosimilar BLAs to FDA for Osteoporosis and Oncology Indications
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced the submission of Biologics License Applications (BLAs)...
Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement
Hanmi Pharm. Co., Ltd. (“Hanmi”) announced a strategic global licensing agreement with Eli Lilly (NYSE:...
Henlius Biotech’s Perjeta Biosimilar HLX11 (Poherdy) Secures NMPA Approval for HER2-Positive Breast Cancer in China
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the National Medical Products Administration (NMPA) has...
True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations
Guangdong True Health Medical Technology Development Co., Ltd., a leading Chinese developer of percutaneous puncture...
Chengdu Kanghua Initiates Phase II Trial for RSV mRNA Vaccine Through NanoRibo Acquisition in China’s Untapped Market
Chengdu Kanghua Biological Products Co., Ltd. (SHE: 300841) announced the initiation of a Phase II...
AbbVie’s VENCLYXTO Receives European Commission Approval for Two Novel Fixed-Duration Combinations in First-Line CLL Treatment
AbbVie (NYSE: ABBV) announced that the European Commission (EC) has granted an expanded marketing authorization...
Beijing Wantai’s 9-Valent HPV Vaccine Achieves Nationwide Distribution Across 13,000 Vaccination Sites in China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced the nationwide commercial launch of...
Bristol-Myers Squibb’s Mezigdomide-Kd Combination Shows 52% Risk Reduction in Relapsed Multiple Myeloma in Phase 3 SUCCESSOR-2 Trial
Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial...
AstraZeneca’s IMFINZI-BCG Combination Approved for High-Risk Non-Muscle-Invasive Bladder Cancer in US
AstraZeneca (NASDAQ: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved IMFINZI...
Merck’s Calderasib-Pembrolizumab Combination Receives FDA Breakthrough Therapy Designation for First-Line KRAS G12C-Mutant NSCLC
Merck & Co., Inc. (MSD; NYSE: MRK) announced that the U.S. Food and Drug Administration...
Eli Lilly’s Retevmo Shows 83% Risk Reduction in Disease Recurrence for Early-Stage RET Fusion-Positive NSCLC in Phase 3 LIBRETTO-432 Trial
Eli Lilly and Company (NYSE: LLY) announced groundbreaking results from the Phase 3 LIBRETTO-432 clinical...
NMPA Opens 2026 National Reimbursement Drug List Application Window with Revised Eligibility Criteria and Price Controls
China’s National Medical Products Administration (NMPA) has released the “2026 Adjustment Work Plan for the...
Teligene’s TL118 Enters NMPA’s SPARK Initiative for Pediatric Cancer Treatment Development
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has included...